FDA estimates the burden of this collection of information as follows:

<table>
<thead>
<tr>
<th>Disclosure regarding additional risks in OTC prescription drug TV ads</th>
<th>Number of respondents</th>
<th>Number of responses per respondent</th>
<th>Total annual responses</th>
<th>Average burden per response</th>
<th>Total hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pilot Study Screener ...............................................</td>
<td>1700 (insomnia), 539 (high cholesterol), 3774 (depression)</td>
<td>1</td>
<td>6,013</td>
<td>0.03 (2 minutes)</td>
<td>180</td>
</tr>
<tr>
<td>Main Study Screener ..................................................</td>
<td>4252 (insomnia), 1347 (high cholesterol), 9433 (depression)</td>
<td>1</td>
<td>15,032</td>
<td>0.03 (2 minutes)</td>
<td>451</td>
</tr>
<tr>
<td>Pilot Study .................................................................</td>
<td>600 (200 for each medical condition)</td>
<td>1</td>
<td>600</td>
<td>0.50 (30 minutes)</td>
<td>300</td>
</tr>
<tr>
<td>Main Study .................................................................</td>
<td>1500 (500 for each medical condition)</td>
<td>1</td>
<td>1500</td>
<td>0.50 (30 minutes)</td>
<td>750</td>
</tr>
<tr>
<td>Total .................................................................</td>
<td>.................................................................</td>
<td>.................................................................</td>
<td>.................................................................</td>
<td>.................................................................</td>
<td>1,681</td>
</tr>
</tbody>
</table>

1 There are no capital costs or operating and maintenance costs associated with this collection of information.

Dated: January 7, 2015.

Leslie Kux,
Associate Commissioner for Policy.

For Further Information Contact:
Patricia Stroup, MBA, MPA, Executive Secretary, Healthcare Systems Bureau, Health Resources and Services Administration, at pstroup@hrsa.gov.

Requests should contain the name, address, telephone number, email address, and any business or professional affiliation of the person desiring to make an oral presentation. Groups having similar interests are requested to combine their comments and present them through a single representative.
DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel; K-awards and R13 conference support review.

Date: February 25, 2015.
Time: 11:30 a.m. to 5:00 p.m.

Place: National Institutes of Health, DEM II, Suite 920, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Manana Sukhareva, Ph.D., Scientific Review Officer, 6707 Democracy Boulevard, Suite 959, Bethesda, MD 20892, 301–451–3397, sukharem@mail.nih.gov.

Dated: January 7, 2015.

Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2015–00292 Filed 1–12–15; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Peer Review Meeting.

Date: February 2, 2015.
Time: 11:00 a.m. to 5:00 p.m.

Place: National Institutes of Health, Room 3E61, 5601 Fishers Lane, Rockville, MD 20852 (Telephone Conference Call).

Contact Person: Raymond R. Schleef, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institutes of Health/ NIAID, 5601 Fishers Lane, Rockville, MD 20852–7616, 240–669–5019, schleefrr@niaid.nih.gov.

Late notification due to delayed response from panel members.

[Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research. National Institutes of Health, HHS]

Dated: January 7, 2015.

Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2015–00292 Filed 1–12–15; 8:45 am]
BILLING CODE 4140–01–P